

07 Feb 2018 | Opinion

In Vivo's Deals Of The Month, January 2018

by Nancy Dvorin

In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)

Top Alliance: Amazon, JP Morgan And Berkshire Hathaway's JV

Details are scarce about the partners' plans to improve health care and reduce its cost for their US employees, yet markets shuddered at the news of this alliance. Considering the rumblings about [Amazon.com Inc.]'s move into health care and the collective clout of these three companies, one might anticipate an impact that reaches beyond their employee base.

Top Financing: BeiGene's FPO

In a month that saw several notable follow-on public offerings, [BeiGene \(Beijing\) Co. Ltd.](#)'s stood out. The Beijing-based immuno-oncology developer netted \$758 million through the sale of 7.9 million American Depositary Shares. Funds will go toward regulatory filings in China for its leading PD-1 and BTK inhibitors as well as business development and R&D. [\[See Deal\]](#)

Top M&A: Celgene Spends \$10 Billion For Juno And Impact

We might have picked [Sanofi](#)'s acquisitions of [Ablynx NV](#) and [Bioverativ Inc.](#), but in the end we opted for [Celgene Corp.](#)'s [Juno Therapeutics Inc.](#) and [Impact Biomedicines](#) buys. The \$9 billion it paid for Juno gives Celgene full ownership of a pipeline of CAR-T therapies. Celgene paid \$1.1 billion up front to acquire Impact and its sole candidate fedratinib, a selective JAK2 kinase inhibitor in Phase III for treatment-naïve myelofibrosis. [\[See Deal\]](#)[\[See Deal\]](#)

